> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 11 Inspection Observations at Dr. Reddy’s Plant
- URL: https://www.fdaweb.com/11-inspection-observations-at-dr-reddys-plant/
- Published: 2017-05-02T12:00:00.000Z
- Updated: 2026-09-14T22:21:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138594

Dr. Reddy’s Laboratories [tells](http://corporates.bseindia.com/xml-data/corpfiling/AttachHis/900620c4-806b-483f-b5c6-1e2d48e56298.pdf?ref=fdaweb.com) stock analysts in India that FDA completed its inspection of the firm’s formulation manufacturing plant at Bachupally, Hyderabad, India, and issued an FDA-483 containing 11 observations. “These observations are mostly procedural in nature,” the firm says, “reflecting the need to improve people capabilities and strengthen documentation and laboratory systems. We will address them comprehensively within the stipulated time.”

In 11/2016, FDA [told](http://fdaweb.com/login.php?sa=v&aid=D5133888&searchWords=dr.%20reddy%27s&cate=S&stid=%241%24Pn2.sB0.%244x6KTuYdDMXt%2FA5gLkmHs1&ref=fdaweb.com) the firm to retain a consultant to assist it meet regulations at three other manufacturing facilities.